Skip to content
Rajiv Vakani
Hyperlipidemia Other triglyceride medicines

Intervention Maps · Hyperlipidemia · Other triglyceride medicines

Other triglyceride-lowering medicines

This page covers triglyceride medicines that are not icosapent ethyl: fibrates first, plus niacin and other prescription omega-3 options as they come up in care. They can change triglycerides. They do not inherit the purified-EPA event results, and they are not presented here as routine add-on event prevention.

Bottom line

Other triglyceride-lowering medicines stay on the map because these medicines still come up when triglycerides are high. Fibrates and niacin can lower triglycerides and remodel lipids, but major statin-era outcome packages do not establish routine add-on ASCVD event prevention. Non-icosapent prescription omega-3s do not inherit REDUCE-IT. They can have specific roles, but the evidence reviewed here does not support treating them as routine add-ons for preventing cardiovascular events.

What it is

Prescription medicines used when triglycerides are high or mixed lipid patterns need attention. Fibrates are the starting branch on this page. Niacin and non-icosapent prescription omega-3 products appear as related options people and clinicians still discuss.

What taking part usually involves

A clinician decides whether any of these belong based on your triglyceride level, other conditions, and what else you're already taking. Follow-up usually includes repeat lipid panels. Niacin's add-on outcome packages also carried important adverse-effect burdens, so side effects belong in the clinical conversation. This page is not a prescribing monograph.

What it is commonly confused with

“High triglycerides means fibrates prevent heart attacks like EPA does.” “Any prescription omega-3 inherits REDUCE-IT.” “If the medicine lowers triglycerides, event prevention is settled.” “This page is here to promote these drugs.”

What the evidence shows

Fibrates and niacin can lower triglycerides and remodel lipids. In major statin-era outcome packages (including FIELD, ACCORD Lipid, AIM-HIGH, HPS2-THRIVE, and related working evidence), that lipid remodeling does not establish routine add-on prevention of ASCVD events.

Non-icosapent prescription omega-3 products must not inherit icosapent ethyl results. If the question is purified EPA event evidence, use that page.

This page exists because these medicines still come up when triglycerides are high. They can have specific roles, but the evidence reviewed here does not support treating them as routine add-ons for preventing cardiovascular events.

Who was studied, expectations, and limits

Population and context studied: adults in statin-era fibrate and niacin outcome programs, plus related triglyceride-medicine practice discussed in major guidelines.

That is the research setting, not a recommendation to start one of these medicines.

Realistic expectation: these medicines can change triglycerides; routine add-on ASCVD event prevention is not established in the packages named here. Limits: no inheritance from icosapent ethyl; not a second EPA story; extreme triglyceride emergencies and pancreatitis pathways are acute safety context, not this page’s chronic map.

Evidence consulted Open sources

Key sources used to prepare this answer. This is not a citation for every sentence.

  1. 2026 ACC/AHA Dyslipidemia Guideline (A1)
  2. 2025 ESC/EAS Focused Update (A2)
  3. NICE NG238 (A3)
  4. Working statin-era outcome packages (FIELD; ACCORD Lipid; AIM-HIGH; HPS2-THRIVE; related) · not seated library sources
  5. REDUCE-IT (NEJM, 2019) (D3) · listed so those results are not transferred here

← Back to Hyperlipidemia · find this again later from “What are you trying to figure out?”